Renal Volume in ADPKD Patient Evaluation
The clinical manifestations of ADPKD are related to the growth of renal cysts. Renal volume has been recognised as the biomarker that is able to identify those patients at risk of complications (hypertension and haematuria) and at risk of progression to End Stage Renal Disease (ESRD). Recently, seve...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | International Journal of Nephrology |
| Online Access: | http://dx.doi.org/10.1155/2020/9286728 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850172664152326144 |
|---|---|
| author | M. Galliani E. Vitaliano S. Chicca L. Calvaruso L. Di Lullo F. Iorio M. E. Tosti A. Paone |
| author_facet | M. Galliani E. Vitaliano S. Chicca L. Calvaruso L. Di Lullo F. Iorio M. E. Tosti A. Paone |
| author_sort | M. Galliani |
| collection | DOAJ |
| description | The clinical manifestations of ADPKD are related to the growth of renal cysts. Renal volume has been recognised as the biomarker that is able to identify those patients at risk of complications (hypertension and haematuria) and at risk of progression to End Stage Renal Disease (ESRD). Recently, several scores have been introduced to predict the evolution of ADPKD. The Mayo Clinic Group developed a classification based on renal volume as measured by CT or MRI and corrected for age and height (Ht-TKV); this allowed predicting the evolution of the disease, but it has not been fully validated so far. In addition, it is used to identify patients labelled as “fast progressors” and eligible for Tolvaptan therapy according to the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) recommendations. We studied 80 patients who underwent MRI and had been classified as ADPKD typical form (class 1A-1E). A significant correlation between renal volume, hypertension, and low GFR was found (p<0.005). A progressive increase in disease severity has been found across the different Mayo classes; 41.2% were eligible for Tolvaptan therapy. The results demonstrate that the Mayo method is easy to perform and provides valid information in order to identify with rapidly progressing disease. |
| format | Article |
| id | doaj-art-cdb1a67932504707a62d34b10ec77611 |
| institution | OA Journals |
| issn | 2090-214X 2090-2158 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Nephrology |
| spelling | doaj-art-cdb1a67932504707a62d34b10ec776112025-08-20T02:20:01ZengWileyInternational Journal of Nephrology2090-214X2090-21582020-01-01202010.1155/2020/92867289286728Renal Volume in ADPKD Patient EvaluationM. Galliani0E. Vitaliano1S. Chicca2L. Calvaruso3L. Di Lullo4F. Iorio5M. E. Tosti6A. Paone7UOC Nefrologia, Dialisi e Litotrissia, Ospedale Sandro Pertini, Roma, ItalyUOC Nefrologia, Dialisi e Litotrissia, Ospedale Sandro Pertini, Roma, ItalyUOC Nefrologia, Dialisi e Litotrissia, Ospedale Sandro Pertini, Roma, ItalyUOC Nefrologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italia, Università Cattolica del Sacro Cuore, Roma, ItalyUOC Nefrologia e Dialisi, Ospedale Delfino Prodi, Colleferro, Roma, ItalyUOC Diagnostica per Immagini, Ospedale Sandro Pertini, ASLRM2, Roma, ItalyNational Center for Global Health, Istituto Superiore di Sanità, Roma, ItalyUOC Nefrologia, Dialisi e Litotrissia, Ospedale Sandro Pertini, Roma, ItalyThe clinical manifestations of ADPKD are related to the growth of renal cysts. Renal volume has been recognised as the biomarker that is able to identify those patients at risk of complications (hypertension and haematuria) and at risk of progression to End Stage Renal Disease (ESRD). Recently, several scores have been introduced to predict the evolution of ADPKD. The Mayo Clinic Group developed a classification based on renal volume as measured by CT or MRI and corrected for age and height (Ht-TKV); this allowed predicting the evolution of the disease, but it has not been fully validated so far. In addition, it is used to identify patients labelled as “fast progressors” and eligible for Tolvaptan therapy according to the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) recommendations. We studied 80 patients who underwent MRI and had been classified as ADPKD typical form (class 1A-1E). A significant correlation between renal volume, hypertension, and low GFR was found (p<0.005). A progressive increase in disease severity has been found across the different Mayo classes; 41.2% were eligible for Tolvaptan therapy. The results demonstrate that the Mayo method is easy to perform and provides valid information in order to identify with rapidly progressing disease.http://dx.doi.org/10.1155/2020/9286728 |
| spellingShingle | M. Galliani E. Vitaliano S. Chicca L. Calvaruso L. Di Lullo F. Iorio M. E. Tosti A. Paone Renal Volume in ADPKD Patient Evaluation International Journal of Nephrology |
| title | Renal Volume in ADPKD Patient Evaluation |
| title_full | Renal Volume in ADPKD Patient Evaluation |
| title_fullStr | Renal Volume in ADPKD Patient Evaluation |
| title_full_unstemmed | Renal Volume in ADPKD Patient Evaluation |
| title_short | Renal Volume in ADPKD Patient Evaluation |
| title_sort | renal volume in adpkd patient evaluation |
| url | http://dx.doi.org/10.1155/2020/9286728 |
| work_keys_str_mv | AT mgalliani renalvolumeinadpkdpatientevaluation AT evitaliano renalvolumeinadpkdpatientevaluation AT schicca renalvolumeinadpkdpatientevaluation AT lcalvaruso renalvolumeinadpkdpatientevaluation AT ldilullo renalvolumeinadpkdpatientevaluation AT fiorio renalvolumeinadpkdpatientevaluation AT metosti renalvolumeinadpkdpatientevaluation AT apaone renalvolumeinadpkdpatientevaluation |